, the interchange of the right sort of data at the prnaeiliccl stage is actually quite problematic (in a previous incarnation I spent a long time trying to do this). One of the big problems is around the definition of what is and isn't a biomarker. Depending where in the value chain the person you ask that is, you'll get very different answers, even if they are expecting to use similar data sources. Indeed one of the bigger issues in that in many cases you need much the same data in biomarker discovery as you do in target discovery or others, it's just a subtly different workflow.Biomarker discovery is though however very susceptible to minimal data standards being too minimal to be of use in this setting.In chemoinfomatics, people are getting used to the fact now that IC50s aren't much use if the assays underneath are significantly different, and assembling lots of disparately sourced data together using this leads to big problems. As Sandor says, generic data standards for biological assays are generally lacking, and workflows for biomarkers are a special case. In which case our project may be mis-named slightly, but points to the real issue around what we're trying to do.It seems to me that things have improved greatly around the exchange of data, yet there are still issues around how (or indeed whether) we exchange enough about how that data itself was generated. I look forward to discussing in more depth!